Page last updated: 2024-12-07

2-hydroxyisovaleric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Hydroxyisovaleric acid (also known as α-hydroxyisovaleric acid) is a branched-chain hydroxy acid that has been studied for its potential therapeutic applications. It has been shown to inhibit the growth of certain types of cancer cells and may also have anti-inflammatory effects. Research on 2-hydroxyisovaleric acid is ongoing, with studies exploring its potential as a drug candidate for a variety of conditions. It is produced by fermentation of glucose using a specific strain of microorganism. The biosynthesis of 2-hydroxyisovaleric acid is catalyzed by the enzyme hydroxymethylglutaryl-CoA reductase.'

2-hydroxyisovaleric acid: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-hydroxy-3-methylbutyric acid : A valine derivative that is valine in which the amino group has been replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID99823
CHEMBL ID1162479
CHEBI ID60645
SCHEMBL ID43434
MeSH IDM0109638

Synonyms (74)

Synonym
600-37-3
4026-18-0
nsc227884
nsc-227884
2-hydroxy-3-methylbutyric acid, 99%
AKOS000278106
2-hydroxyisovaleric acid
2-hydroxyisovalerate
2-oxyisovalerate
2-hydroxy-3-methylbutyric acid
alpha-hydroxyisovaleric acid
2-hydroxy-3-methylbutanoic acid
2-hydroxyisopentanoic acid
3-methyl-2-hydroxybutyric acid
CHEBI:60645 ,
FT-0659220
FT-0691710
inchi=1/c5h10o3/c1-3(2)4(6)5(7)8/h3-4,6h,1-2h3,(h,7,8)
ngewqzidqiyunv-uhfffaoysa-
CHEMBL1162479
A825017
3-methyl-2-oxidanyl-butanoic acid
unii-02x1w97fwn
(1)-2-hydroxy-3-methylbutyric acid
einecs 209-994-2
nsc 227884
einecs 223-697-5
02x1w97fwn ,
FT-0635106
S6098
( inverted exclamation marka)-2-hydroxyisopentanoic acid
dl-2-hydroxy-3-methylbutanoic acid
2-oxyisovaleric acid
dl-2-hydroxyisovaleric acid
AKOS016182980
SCHEMBL43434
2-hydroxy-3-methylbutanoic acid #
butanoic acid, 2-hydroxy-3-methyl-
W-106368
l-valic acid
d-valic acid
(+/-)-2-hydroxyisopentanoic acid
dl-.alpha.-hydroxyisovaleric acid
.alpha.-hydroxyisovaleric acid
(+/-)-2-hydroxyisovaleric acid
butyric acid, 2-hydroxy-3-methyl-
(+/-)-.alpha.-hydroxyisovaleric acid
(+/-)-2-hydroxy-3-methylbutyric acid
butanoic acid,2-hydroxy-3-methyl-,(2r)-
LMFA01050478
CS-W008150
mfcd00004242
dl-alpha-hydroxyisovaleric acid
dl-a-hydroxyisovaleric acid
a-hydroxyisovaleric acid
HY-W008150
DTXSID10863305
SY041974
F19720
2-hydroxy-3-methyl butyric acid
Q27104874
(rs)-2-hydroxyisovaleric acid
AS-12349
2-methylpyridine-4-boronic?acid?pinacol?ester
AMY22056
d-alpha-hydroxyisovalericacid
(r)-2-hydroxyisovaleric acid;d-alpha-hydroxyisovaleric acid
BCP33335
BCP33333
AB88448
2-hydroxy-3-methylbutanoicacid
PD099517
EN300-115018
SY066296
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-hydroxy monocarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki315.61401.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki14,162.70020.40745.02179.4000AID360150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (28.57)18.7374
1990's4 (14.29)18.2507
2000's7 (25.00)29.6817
2010's8 (28.57)24.3611
2020's1 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.87 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index28.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (10.71%)4.05%
Observational0 (0.00%)0.25%
Other25 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]